Table 4.

Secondary Malignancy Outcomes

Variable	Ruxolitinib naïve (N=73)	Ruxolitinib Treated (N=202)	Total (N=275)	P Value
Secondary Malignancy, Yes, N(%)	4 (5.5%)	9 (4.5%)	13 (4.7%)	0.724
Type of Cancers, N(%)				0.733
Squamous cell carcinoma	1 (1.4%)	3 (1.5%)	3 (1.1%)
Basal cell carcinoma	1 (1.4%)	1 (0.5%)	1 (0.4%)
Bladder cancer	0 (0.0%)	1 (0.5%)	1 (0.4%)
Diffuse large B-cell lymphoma	0 (0.0%)	1 (0.5%)	1 (0.4%)
Hodgkin’s lymphoma	1 (1.4%)	0 (0.0%)	1 (0.4%)
Lung adenocarcinoma	0 (0.0%)	1 (0.5%)	1 (0.4%)
Multiple myeloma	0 (0.0%)	1 (0.5%)	1 (0.4%)
Rectal carcinoma	0 (0.0%)	1 (0.5%)	1 (0.4%)
Pleomorphic carcinoma of lung	1 (1.4%)	0 (0.0%)	1 (0.4%)
Acute Leukemia, Yes, N(%)	2 (2.7%)	18 (8.9%)	20 (7.3%)	0.082